KAPA
Kairos Pharma, Ltd.
Price Chart
Latest Quote
$0.37
-0.05 (-10.78%)
Current Price
| Previous Close | $0.42 |
| Open | $0.42 |
| Day High | $0.42 |
| Day Low | $0.37 |
| Volume | 332,156 |
Stock Information
| Shares Outstanding | 21.41M |
| Cash Equivalents | $3.67M |
| Net Income | $-5.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.02M |
| EPS (TTM) | $-0.30 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.35M |
| Income | $-5.84M |
| Book/sh | $0.25 |
| Cash/sh | $0.17 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 8.53 |
| Current Ratio | 10.31 |
Returns & Margins
| ROA | -54.78% |
| ROE | -93.84% |
Ownership
| Insider Ownership | 37.20% |
| Institutional Ownership | 6.94% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.56 |
| P/B | 1.51 |
Analyst Data
| Recommendation | none |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $0.45 |
| SMA50 | $0.52 |
| SMA200 | $0.77 |
| RSI | 27.59 |
| ATR | 0.0321 |
| Shares Float | 13.42M |
| Short Float | 1.06% |
| Short Ratio | 1.04 |
| Rel Volume | 2.97 |
Performance History
| Week | -17.94% |
| Month | -27.47% |
| Quarter | -37.71% |
| 6 Months | -53.42% |
| YTD | -48.56% |
| Year | -42.22% |
| 10 Years | -85.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $0.38 | 335,800 |
| 2026-06-24 | $0.42 | 104,600 |
| 2026-06-23 | $0.43 | 39,300 |
| 2026-06-22 | $0.43 | 63,000 |
| 2026-06-18 | $0.43 | 102,900 |
| 2026-06-17 | $0.46 | 53,200 |
| 2026-06-16 | $0.45 | 72,100 |
| 2026-06-15 | $0.44 | 65,700 |
| 2026-06-12 | $0.44 | 173,100 |
| 2026-06-11 | $0.46 | 116,100 |
| 2026-06-10 | $0.43 | 87,900 |
| 2026-06-09 | $0.43 | 91,600 |
| 2026-06-08 | $0.45 | 98,200 |
| 2026-06-05 | $0.44 | 88,200 |
| 2026-06-04 | $0.47 | 116,900 |
| 2026-06-03 | $0.46 | 217,100 |
| 2026-06-02 | $0.47 | 159,000 |
| 2026-06-01 | $0.49 | 90,200 |
| 2026-05-29 | $0.51 | 126,000 |
| 2026-05-28 | $0.53 | 61,100 |
| 2026-05-27 | $0.52 | 105,400 |
| 2026-05-26 | $0.52 | 52,600 |
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $189,000 | $98,000 | $459,000 |
| Total Expenses | $5,572,000 | $2,343,000 | $1,714,000 | $571,000 |
| Net Non Operating Interest Income Expense | $125,000 | $-859,000 | $-98,000 | $-479,000 |
| Interest Expense Non Operating | $0 | $189,000 | $98,000 | $459,000 |
| Operating Expense | $5,572,000 | $2,343,000 | $1,714,000 | $571,000 |
| General And Administrative Expense | $3,277,000 | $1,769,000 | $1,472,000 | $324,000 |
| Other Income Expense | - | $599,000 | - | - |
| Total Other Finance Cost | - | $670,000 | $56,000 | $20,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Net Interest Income | $125,000 | $-859,000 | $-98,000 | $-479,000 |
| Interest Income | $125,000 | $0 | - | - |
| Normalized Income | $-5,447,000 | $-3,202,000 | $-1,812,000 | $-1,050,000 |
| Net Income From Continuing And Discontinued Operation | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Total Operating Income As Reported | $-5,572,000 | $-2,343,000 | $-1,714,000 | $-571,000 |
| Net Income Common Stockholders | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Net Income | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Net Income Including Noncontrolling Interests | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Net Income Continuous Operations | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Pretax Income | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Special Income Charges | $0 | $599,000 | $0 | - |
| Interest Income Non Operating | $125,000 | $0 | - | - |
| Operating Income | $-5,572,000 | $-2,343,000 | $-1,714,000 | $-571,000 |
| Depreciation Amortization Depletion Income Statement | $160,000 | $160,000 | $160,000 | $160,000 |
| Depreciation And Amortization In Income Statement | $160,000 | $160,000 | $160,000 | $160,000 |
| Amortization Of Intangibles Income Statement | $160,000 | $160,000 | $160,000 | $160,000 |
| Per Share | ||||
| Diluted EPS | $-0.30 | $-0.23 | $-0.16 | $-0.10 |
| Basic EPS | $-0.30 | $-0.23 | $-0.16 | $-0.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,287,000 | $-2,853,000 | $-1,554,000 | $-431,000 |
| Total Unusual Items | $0 | $599,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $599,000 | $0 | - |
| Reconciled Depreciation | $160,000 | $160,000 | $160,000 | $160,000 |
| EBITDA (Bullshit earnings) | $-5,287,000 | $-2,254,000 | $-1,554,000 | $-431,000 |
| EBIT | $-5,447,000 | $-2,414,000 | $-1,714,000 | $-591,000 |
| Diluted Average Shares | $18,427,787 | $11,356,451 | $11,215,807 | $10,839,452 |
| Basic Average Shares | $18,427,787 | $11,356,451 | $11,215,807 | $10,839,452 |
| Diluted NI Availto Com Stockholders | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Amortization | $160,000 | $160,000 | $160,000 | $160,000 |
| Research And Development | $2,135,000 | $414,000 | $82,000 | $87,000 |
| Selling General And Administration | $3,277,000 | $1,769,000 | $1,472,000 | $324,000 |
| Other Gand A | $2,551,000 | $1,399,000 | $530,000 | $304,000 |
| Insurance And Claims | $385,000 | $151,000 | $29,000 | $20,000 |
| Salaries And Wages | $341,000 | $219,000 | $913,000 | $0 |
| Other Special Charges | - | $-599,000 | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,279,000 | $4,554,000 | $-2,460,000 | $-1,721,000 |
| Total Assets | $6,540,000 | $5,768,000 | $965,000 | $1,036,000 |
| Total Non Current Assets | $1,153,000 | $1,599,000 | $864,000 | $599,000 |
| Non Current Deferred Assets | $1,091,000 | $1,377,000 | $482,000 | $57,000 |
| Goodwill And Other Intangible Assets | $62,000 | $222,000 | $382,000 | $542,000 |
| Other Intangible Assets | $62,000 | $222,000 | $382,000 | $542,000 |
| Current Assets | $5,387,000 | $4,169,000 | $101,000 | $437,000 |
| Other Current Assets | $51,000 | $38,000 | $8,000 | - |
| Prepaid Assets | $845,000 | $2,859,000 | $0 | $0 |
| Cash Cash Equivalents And Short Term Investments | $4,491,000 | $1,272,000 | $93,000 | $437,000 |
| Cash And Cash Equivalents | $4,491,000 | $1,272,000 | $93,000 | $437,000 |
| Cash Financial | - | $1,272,000 | $93,000 | $437,000 |
| Debt | ||||
| Net Debt | - | - | $545,000 | $145,000 |
| Total Debt | - | - | $638,000 | $582,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $638,000 | $582,000 |
| Long Term Debt | - | - | $638,000 | $582,000 |
| Current Debt And Capital Lease Obligation | - | - | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $199,000 | $992,000 | $3,043,000 | $2,215,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $638,000 | $582,000 |
| Current Liabilities | $199,000 | $992,000 | $2,405,000 | $1,633,000 |
| Payables And Accrued Expenses | $199,000 | $992,000 | $2,405,000 | $1,633,000 |
| Payables | $199,000 | $992,000 | $2,405,000 | $1,633,000 |
| Accounts Payable | $199,000 | $992,000 | $2,401,000 | $1,629,000 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $6,341,000 | $4,776,000 | $-2,078,000 | $-1,179,000 |
| Total Equity Gross Minority Interest | $6,341,000 | $4,776,000 | $-2,078,000 | $-1,179,000 |
| Stockholders Equity | $6,341,000 | $4,776,000 | $-2,078,000 | $-1,179,000 |
| Retained Earnings | $-14,262,000 | $-8,815,000 | $-6,212,000 | $-4,400,000 |
| Other | ||||
| Ordinary Shares Number | $20,821,353 | $13,736,597 | $12,841,937 | $12,841,937 |
| Share Issued | $20,821,353 | $13,736,597 | $12,841,937 | $12,841,937 |
| Tangible Book Value | $6,279,000 | $4,554,000 | $-2,460,000 | $-1,721,000 |
| Invested Capital | $6,341,000 | $4,776,000 | $-1,440,000 | $-597,000 |
| Working Capital | $5,188,000 | $3,177,000 | $-2,304,000 | $-1,196,000 |
| Total Capitalization | $6,341,000 | $4,776,000 | $-1,440,000 | $-597,000 |
| Additional Paid In Capital | $20,582,000 | $13,577,000 | $4,123,000 | $3,211,000 |
| Capital Stock | $21,000 | $14,000 | $11,000 | $10,000 |
| Common Stock | $21,000 | $14,000 | $11,000 | $10,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | - | $0 | $4,000 | $4,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,441,000 | $-3,955,000 | $81,000 | $-353,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,441,000 | $-3,955,000 | $81,000 | $-353,000 |
| Cash Flow From Continuing Operating Activities | $-3,441,000 | $-3,955,000 | $81,000 | $-353,000 |
| Operating Gains Losses | - | $29,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | - | - | $0 |
| Cash Flow From Continuing Investing Activities | - | - | - | $0 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $5,524,000 | $0 | $0 |
| Financing Cash Flow | $6,660,000 | $5,134,000 | $-425,000 | $717,000 |
| Cash Flow From Continuing Financing Activities | $6,660,000 | $5,134,000 | $-425,000 | $717,000 |
| Net Other Financing Charges | $3,602,000 | $-390,000 | $-425,000 | $-178,000 |
| Net Common Stock Issuance | $0 | $5,524,000 | $0 | $0 |
| Common Stock Issuance | $0 | $5,524,000 | $0 | $0 |
| Other | ||||
| Issuance Of Debt | $0 | $142,000 | $0 | $925,000 |
| Interest Paid Supplemental Data | $0 | $3,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $4,491,000 | $1,272,000 | $93,000 | $437,000 |
| Beginning Cash Position | $1,272,000 | $93,000 | $437,000 | $73,000 |
| Changes In Cash | $3,219,000 | $1,179,000 | $-344,000 | $364,000 |
| Proceeds From Stock Option Exercised | $3,058,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $0 | $0 | $0 | $895,000 |
| Net Long Term Debt Issuance | $0 | $0 | $0 | $895,000 |
| Long Term Debt Issuance | $0 | $142,000 | $0 | $925,000 |
| Change In Working Capital | $-806,000 | $-1,984,000 | $764,000 | $129,000 |
| Change In Payables And Accrued Expense | $-793,000 | $404,000 | $772,000 | $129,000 |
| Change In Prepaid Assets | $-13,000 | $-2,388,000 | $-8,000 | $0 |
| Other Non Cash Items | $2,652,000 | $443,000 | $969,000 | $408,000 |
| Depreciation Amortization Depletion | $160,000 | $160,000 | $160,000 | $160,000 |
| Depreciation And Amortization | $160,000 | $160,000 | $160,000 | $160,000 |
| Amortization Cash Flow | $160,000 | $160,000 | $160,000 | $160,000 |
| Amortization Of Intangibles | $160,000 | $160,000 | $160,000 | $160,000 |
| Net Income From Continuing Operations | $-5,447,000 | $-2,603,000 | $-1,812,000 | $-1,050,000 |
| Repayment Of Debt | - | $-142,000 | $0 | $-30,000 |
| Long Term Debt Payments | - | $-142,000 | $0 | $-30,000 |
| Change In Other Working Capital | - | $-2,358,000 | - | - |
| Stock Based Compensation | - | $218,000 | $0 | $0 |
| Gain Loss On Investment Securities | - | $29,000 | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-23